{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:46:01Z","timestamp":1792788361987,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Deltamune","id":[{"id":"https:\/\/ror.org\/01bnv2160","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Dutch Ministry of Economic Affairs","id":[{"id":"https:\/\/ror.org\/00bc6bw85","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.vaccine.2018.03.003","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:11:09Z","timestamp":1520467869000},"page":"1925-1933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3\/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform"],"prefix":"10.1016","volume":"36","author":[{"given":"Piet A.","family":"van Rijn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke A.","family":"Maris-Veldhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiaan A.","family":"Potgieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 G.P.","family":"van Gennip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.03.003_b0005","unstructured":"Theiler A. African Horse sickness. Sci Bull 1921;19."},{"key":"10.1016\/j.vaccine.2018.03.003_b0010","doi-asserted-by":"crossref","unstructured":"Erasmus BJ. The pathogenesis of African Horsesickness. In: Proceedings of the 3rd int conf equine infectious diseases. Paris: Karger, Basel; 1973. p. 1\u201311.","DOI":"10.1159\/000393512"},{"key":"10.1016\/j.vaccine.2018.03.003_b0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/vr.101083","article-title":"Outbreaks of African horse sickness in Senegal, and methods of control of the 2007 epidemic","volume":"172","author":"Diouf","year":"2013","journal-title":"Vet Rec"},{"key":"10.1016\/j.vaccine.2018.03.003_b0020","first-page":"216","article-title":"Horse sickness","volume":"56","author":"Rafyi","year":"1961","journal-title":"Bull Off Int Epizoot"},{"key":"10.1016\/j.vaccine.2018.03.003_b0025","first-page":"23","article-title":"A review of the aetiology and pathology of African horsesickness","volume":"25","author":"Mirchamsy","year":"1973","journal-title":"Arch Hessarek Iran"},{"key":"10.1016\/j.vaccine.2018.03.003_b0030","first-page":"329","article-title":"The 1960 epizootic of African horsesickness in the Middle East and SW Asia","volume":"31","author":"Howell","year":"1960","journal-title":"J South Afr Vet Assoc"},{"key":"10.1016\/j.vaccine.2018.03.003_b0035","series-title":"African horsesickness","first-page":"460","article-title":"Infectious disease of livestock with special reference to southern Africa","author":"Coetzer","year":"1994"},{"key":"10.1016\/j.vaccine.2018.03.003_b0040","unstructured":"Lubroth J, \u201333. EP. African horsesickness and the epizootic in Spain 1987. Equine Pract 1988;10:26\u201333."},{"key":"10.1016\/j.vaccine.2018.03.003_b0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1051\/vetres:2004021","article-title":"African horse sickness","volume":"35","author":"Mellor","year":"2004","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2018.03.003_b0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0378-1135(92)90041-Q","article-title":"African horse sickness in Spain","volume":"33","author":"Rodriguez","year":"1992","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2915.2003.00419.x","article-title":"Spatial distribution of Culicoides species in Portugal in relation to the transmission of African horse sickness and bluetongue viruses","volume":"17","author":"Capela","year":"2003","journal-title":"Med Vet Entomol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0060","unstructured":"Mertens PPC, Maan S, Samuel A, Attoui H. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, editors. Virus taxonomy VIIIth report of the ICTV. London: Elsevier\/Academic Press; 2005. p. 466\u201383."},{"key":"10.1016\/j.vaccine.2018.03.003_b0065","first-page":"465","article-title":"Immunological types of horsesickness virus and their significance in immunization","volume":"27","author":"McIntosh","year":"1958","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2018.03.003_b0070","first-page":"139","article-title":"The isolation and identification of further antigenic types of African horsesickness virus","volume":"29","author":"Howell","year":"1962","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2018.03.003_b0075","doi-asserted-by":"crossref","first-page":"e1002477","DOI":"10.1371\/journal.ppat.1002477","article-title":"Identification and characterization of a novel non-structural protein of bluetongue virus","volume":"7","author":"Ratinier","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.03.003_b0080","doi-asserted-by":"crossref","first-page":"e25697","DOI":"10.1371\/journal.pone.0025697","article-title":"Detection of a fourth orbivirus non-structural protein","volume":"6","author":"Belhouchet","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.03.003_b0085","first-page":"7","article-title":"The transmission of blue-tongue and n horse sickness by Culicoides","volume":"19","author":"Du Toit","year":"1944","journal-title":"Onderstepoort J Vet Sci Anim Ind"},{"key":"10.1016\/j.vaccine.2018.03.003_b0090","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2915.2000.00245.x","article-title":"African horse sickness epidemiology: vector competence of South African Culicoides species for virus serotypes 3, 5 and 8","volume":"14","author":"Venter","year":"2000","journal-title":"Med Vet Entomol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0095","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2915.2007.00706.x","article-title":"Virus recovery rates for wild-type and live-attenuated vaccine strains of African horse sickness virus serotype 7 in orally infected South African Culicoides species","volume":"21","author":"Venter","year":"2007","journal-title":"Med Vet Entomol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrmicro1090","article-title":"Climate change and the recent emergence of bluetongue in Europe","volume":"3","author":"Purse","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0105","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1017\/S0950268809990367","article-title":"Assessing the impact of climate change on vector-borne viruses in the EU through the elicitation of expert opinion","volume":"138","author":"Gale","year":"2010","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2018.03.003_b0110","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/vr.161.16.564","article-title":"Potential new Culicoides vector of bluetongue virus in northern Europe","volume":"161","author":"Meiswinkel","year":"2007","journal-title":"Vet Rec"},{"key":"10.1016\/j.vaccine.2018.03.003_b0115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00436-007-0519-6","article-title":"First occurrence of Culicoides obsoletus-transmitted Bluetongue virus epidemic in Central Europe","volume":"101","author":"Mehlhorn","year":"2007","journal-title":"Parasitol Res"},{"key":"10.1016\/j.vaccine.2018.03.003_b0120","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/vr.162.13.422-a","article-title":"Culicoides chiopterus as a potential vector of bluetongue virus in Europe","volume":"162","author":"Dijkstra","year":"2008","journal-title":"Vet Rec"},{"key":"10.1016\/j.vaccine.2018.03.003_b0125","doi-asserted-by":"crossref","first-page":"e23066","DOI":"10.1371\/journal.pone.0023066","article-title":"Transmission and control of African horse sickness in The Netherlands: a model analysis","volume":"6","author":"Backer","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.03.003_b0130","article-title":"Comparative risk analysis of two Culicoides-borne diseases in horses: equine encephalosis more likely to enter France than African horse sickness","author":"Faverjon","year":"2016","journal-title":"Transbound Emerg Dis"},{"key":"10.1016\/j.vaccine.2018.03.003_b0135","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3201\/eid2212.160718","article-title":"African horse sickness caused by genome reassortment and reversion to virulence of live, attenuated vaccine viruses, South Africa, 2004\u20132014","volume":"22","author":"Weyer","year":"2016","journal-title":"Emerg Infect Dis"},{"issue":"Pt 9","key":"10.1016\/j.vaccine.2018.03.003_b0140","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1099\/0022-1317-77-9-2053","article-title":"Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge","volume":"77","author":"Roy","year":"1996","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0145","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0264-410X(01)00445-5","article-title":"The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant","volume":"20","author":"Scanlen","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.003_b0150","doi-asserted-by":"crossref","first-page":"e16503","DOI":"10.1371\/journal.pone.0016503","article-title":"A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR\u2212\/\u2212 mouse model","volume":"6","author":"Castillo-Olivares","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.03.003_b0155","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vetimm.2012.06.009","article-title":"An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses","volume":"149","author":"El Garch","year":"2012","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virusres.2013.12.002","article-title":"Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation","volume":"180","author":"Calvo-Pinilla","year":"2014","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.03.003_b0165","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.vaccine.2014.04.036","article-title":"Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge","volume":"32","author":"Alberca","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.003_b0170","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/1040841X.2016.1186005","article-title":"Current and next-generation bluetongue vaccines: requirements, strategies, and prospects for different field situations","volume":"43","author":"Feenstra","year":"2017","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0175","doi-asserted-by":"crossref","first-page":"9856","DOI":"10.1128\/JVI.01514-13","article-title":"Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep","volume":"87","author":"Celma","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0180","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01892-16","article-title":"Replication-deficient particles: new insights into the next generation of bluetongue virus vaccines","volume":"91","author":"Celma","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0185","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1016\/j.vaccine.2014.10.033","article-title":"VP2-serotyped live-attenuated bluetongue virus without NS3\/NS3a expression provides serotype-specific protection and enables DIVA","volume":"32","author":"Feenstra","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.003_b0190","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.vaccine.2014.12.003","article-title":"Application of Bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2","volume":"33","author":"Feenstra","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.003_b0195","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1099\/vir.0.065615-0","article-title":"Bluetongue virus without NS3\/NS3a expression is not virulent and protects against virulent bluetongue virus challenge","volume":"95","author":"Feenstra","year":"2014","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0200","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s13071-015-1063-3","article-title":"Non-structural protein NS3\/NS3a is required for propagation of bluetongue virus in Culicoides sonorensis","volume":"8","author":"Feenstra","year":"2015","journal-title":"Parasit Vect"},{"key":"10.1016\/j.vaccine.2018.03.003_b0205","doi-asserted-by":"crossref","first-page":"10213","DOI":"10.1128\/JVI.05412-11","article-title":"Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge","volume":"85","author":"Matsuo","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0210","doi-asserted-by":"crossref","first-page":"8764","DOI":"10.1128\/JVI.01052-15","article-title":"VP2 exchange and NS3\/NS3a deletion in African horse sickness virus (AHSV) in development of Disabled Infectious Single Animal vaccine candidates for AHSV","volume":"89","author":"van de Water","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0215","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00548-16","article-title":"Assembly of replication-incompetent African horse sickness virus particles: rational design of vaccines for all serotypes","author":"Lulla","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0220","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF01314778","article-title":"Persistent infection of BHK21\/WI-2 cells with rubella virus and characterization of rubella variants","volume":"54","author":"Sato","year":"1977","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0225","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0022-2011(89)90123-7","article-title":"Cell lines from Culicoides variipennis (Diptera: Ceratopogonidae) support replication of bluetongue virus","volume":"54","author":"Wechsler","year":"1989","journal-title":"J Invertebr Pathol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0230","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12985-016-0574-7","article-title":"Requirements and comparative analysis of reverse genetics for bluetongue virus (BTV) and African horse sickness virus (AHSV)","volume":"13","author":"van Rijn","year":"2016","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2018.03.003_b0235","first-page":"3","article-title":"Consensus sequence of 27 african horse sickness virus genomes from viruses collected over a 76-year period, to 2009)","volume":"1993","author":"Potgieter","year":"2015","journal-title":"Genome Announc"},{"key":"10.1016\/j.vaccine.2018.03.003_b0240","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1099\/vir.0.009381-0","article-title":"Improved strategies for sequence-independent amplification and sequencing of viral double-stranded RNA genomes","volume":"90","author":"Potgieter","year":"2009","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0245","doi-asserted-by":"crossref","first-page":"e85788","DOI":"10.1371\/journal.pone.0085788","article-title":"Bluetongue virus nonstructural protein NS3\/NS3a is not essential for virus replication","volume":"9","author":"van Gennip","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.03.003_b0250","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01328-16","article-title":"Structural protein VP2 of african horse sickness virus is not essential for virus replication in vitro","volume":"91","author":"van Gennip","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0255","first-page":"171","article-title":"The cytopathic action of Bluetongue virus on tissue cultures and its application to the detection of antibodies in the serum of sheep","volume":"27","author":"Haig","year":"1956","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2018.03.003_b0260","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/1040638712440986","article-title":"Sustained high-throughput polymerase chain reaction diagnostics during the European epidemic of Bluetongue virus serotype 8","volume":"24","author":"van Rijn","year":"2012","journal-title":"J Vet Diagn Invest"},{"key":"10.1016\/j.vaccine.2018.03.003_b0265","doi-asserted-by":"crossref","first-page":"e30540","DOI":"10.1371\/journal.pone.0030540","article-title":"Rescue of recent virulent and avirulent field strains of bluetongue virus by reverse genetics","volume":"7","author":"van Gennip","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.03.003_b0270","doi-asserted-by":"crossref","first-page":"e92377","DOI":"10.1371\/journal.pone.0092377","article-title":"RNA elements in open reading frames of the bluetongue virus genome are essential for virus replication","volume":"9","author":"Feenstra","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.03.003_b0275","doi-asserted-by":"crossref","first-page":"e1005056","DOI":"10.1371\/journal.ppat.1005056","article-title":"Widespread reassortment shapes the evolution and epidemiology of bluetongue virus following European invasion","volume":"11","author":"Nomikou","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.03.003_b0280","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virusres.2016.04.007","article-title":"African horse sickness virus serotype 4 antigens, VP1-1, VP2-2, VP4, VP7 and NS3, induce cytotoxic T cell responses in vitro","volume":"220","author":"Faber","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.03.003_b0285","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.vetimm.2012.01.016","article-title":"Virus-specific CD8(+) T-cells detected in PBMC from horses vaccinated against African horse sickness virus","volume":"146","author":"Pretorius","year":"2012","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0290","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.imbio.2015.09.002","article-title":"Immune gene expression profiling of PBMC isolated from horses vaccinated with attenuated African horsesickness virus serotype 4","volume":"221","author":"Pretorius","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.vaccine.2018.03.003_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2017.06.023","article-title":"Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge","author":"Lulla","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.003_b0300","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.vaccine.2016.11.081","article-title":"Bluetongue Disabled Infectious Single Animal (DISA) vaccine: studies on the optimal route and dose in sheep","volume":"35","author":"van Rijn","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.03.003_b0305","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0168-1656(99)00121-2","article-title":"Diva vaccines that reduce virus transmission","volume":"73","author":"van Oirschot","year":"1999","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2018.03.003_b0310","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0168-1702(95)00061-T","article-title":"The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses","volume":"38","author":"Laviada","year":"1995","journal-title":"Virus Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830330X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1830330X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T09:00:44Z","timestamp":1570870844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1830330X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":62,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0264410X1830330X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3\/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}